Microbiology News and Research

RSS

Optimer third quarter net loss increases to $11.8 million

Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.

2 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

Thomson Reuters launches Pharmacy Xpert dashboard to manage medication therapy

Thomson Reuters, a global provider of information for healthcare professionals, today announced the launch of Thomson Reuters Pharmacy Xpert the first-of-its-kind clinical intelligence dashboard that helps hospital pharmacists better manage medication therapy to improve outcomes, reduce costs, and manage risk.

2 Nov 2010

Short courses of antibiotics have long-term impact on microbial flora of human gut

Short courses of antibiotics can leave normal gut bacteria harbouring antibiotic resistance genes for up to two years after treatment, say scientists writing in the latest issue of Microbiology, published on 3 November.

1 Nov 2010

GlycosBio, Malaysian Bio-XCell enter agreement to build biochemical plant and biotechnology R&D facility

Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today exchanged definitive agreements with Malaysian Bio-XCell for the establishment of the Company's industrial biochemical plant and biotechnology R&D facility in Malaysia

1 Nov 2010

FDA awards 84 grants worth $18.5 million to boost food and feed safety initiatives

The U.S. Food and Drug Administration awarded 84 grants worth $18.5 million in fiscal year 2010 to help state and local regulatory agencies defend against and respond quickly to threats to the food supply and to outbreaks of foodborne diseases.

29 Oct 2010

Scientists identify potential new treatment for Nipah and Hendra viruses

Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available. The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens.

29 Oct 2010

Lippincott Williams & Wilkins to publish journal Pathology

Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health, announced today that it has signed an agreement to serve as exclusive publisher of Pathology effective January 1, 2011. The Royal College of Pathologists of Australasia (RCPA), which produces Pathology, is responsible for the training and professional development of pathologists and for the promotion of the science and practice of pathology.

27 Oct 2010

Study: lncRNA are involved in host response to viral infection

Scientists have demonstrated for the first time that a certain class of RNA (known as long non-protein-coding RNA [lncRNA]) are involved in the host response to viral infection. These findings, published today in the online journal mBio-, could greatly change the way scientists look at the body's response to viral infection.

27 Oct 2010

University of Padua Professor wins Paul Ehrlich and Ludwig Darmstaedter Prize

Frankfurt am Main. The chemist and biologist Professor Cesare Montecucco, 62, of the Department of Biomedical Research at the University of Padua, Italy, has won the 100,000 euro Paul Ehrlich and Ludwig Darmstaedter Prize 2011 for his contribution to research in the field of bacterial diseases, including tetanus, botulism, anthrax and Helicobacter pylori associated diseases.

27 Oct 2010

Long non-protein coding RNAs respond to SARS virus infection, says study

For the first time, scientists have discovered that a poorly understood class of RNA produced in a mammal's cells during a respiratory virus attack may affect the outcome of the infection. Their findings are reported today in mBio, a journal of the American Society for Microbiology.

27 Oct 2010

Pathogenic listeria tricks intestinal cells to cause sickness

Pathogenic listeria tricks intestinal cells into helping it pass through those cells to make people ill, and, if that doesn't work, the bacteria simply goes around the cells, according to a Purdue University study.

26 Oct 2010

Incidence of KPC-producing bacteria is rising in Chicago

In a survey of Chicago-area healthcare facilities, researchers at Rush University Medical Center and the Cook County Department of Public Health have found that the incidence of KPC-producing bacteria is rising. These bugs cause infections with high mortality rates and are resistant to the most commonly used antibiotics.

25 Oct 2010

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.

25 Oct 2010

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

Scientists and engineers from around the world will gather on the shores of Lake Ontario in Rochester, N.Y. next week to discuss some of the latest breakthroughs in lasers and optics and their applications to cutting-edge science, the development of new materials, and medicine.

21 Oct 2010

RWV bioreactor creates 3-D cell culture models

The cells and tissues in our bodies grow, develop and interact in a highly complex, three-dimensional world. Likewise, the various microbial pathogens that invade our bodies and cause infectious disease interact with this complex 3-D tissue milieu. In the current issue of the journal Nature Reviews Microbiology, researcher Cheryl Nickerson and her team at the Biodesign Institute at Arizona State University highlight an innovative approach for studying cells in 3-D.

20 Oct 2010

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer – triple-negative breast cancer. The research is exclusive to the Karmanos Cancer Institute.

19 Oct 2010

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.

18 Oct 2010

CIHR, Genome BC announce $5.4 million for microbiome research

The University of British Columbia today welcomed the announcement of $5.4 million in funding from the Canadian Institutes of Health Research (CIHR) and Genome British Columbia for research into how micro-organisms affect human health.

15 Oct 2010

Infection during pregnancy linked to increased risk for neurodevelopmental disorders in fetus

A pregnant woman's immune response to viral infections may induce subtle neurological changes in the unborn child that can lead to an increased risk for neurodevelopmental disorders including schizophrenia and autism. Research published in the online journal mBio- provides new insights into how this may happen and suggests potential strategies for reducing this risk.

13 Oct 2010

Microbiology News and Research

Optimer third quarter net loss increases to $11.8 million

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Thomson Reuters launches Pharmacy Xpert dashboard to manage medication therapy

Short courses of antibiotics have long-term impact on microbial flora of human gut

GlycosBio, Malaysian Bio-XCell enter agreement to build biochemical plant and biotechnology R&D facility

FDA awards 84 grants worth $18.5 million to boost food and feed safety initiatives

Scientists identify potential new treatment for Nipah and Hendra viruses

Lippincott Williams & Wilkins to publish journal Pathology

Study: lncRNA are involved in host response to viral infection

University of Padua Professor wins Paul Ehrlich and Ludwig Darmstaedter Prize

Long non-protein coding RNAs respond to SARS virus infection, says study

Pathogenic listeria tricks intestinal cells to cause sickness

Incidence of KPC-producing bacteria is rising in Chicago

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

RWV bioreactor creates 3-D cell culture models

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

CIHR, Genome BC announce $5.4 million for microbiome research

Infection during pregnancy linked to increased risk for neurodevelopmental disorders in fetus

Microbiology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News